Tarsus Pharmaceuticals
TARS
116 hedge funds and large institutions have $652M invested in Tarsus Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 48 increasing their positions, 22 reducing their positions, and 17 closing their positions.
552% more call options, than puts
Call options by funds: $2.99M | Put options by funds: $458K
118% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 22
65% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 17
23% more capital invested
Capital invested by funds: $529M → $652M (+$123M)
10% more funds holding
Funds holding: 105 → 116 (+11)
5.86% more ownership
Funds ownership: 91.33% → 97.19% (+5.9%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$31.5M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$17.1M |
| 3 |
BlackRock
New York
|
+$5.11M |
| 4 |
RI
RTW Investments
New York
|
+$4.54M |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$13.4M |
| 2 |
Millennium Management
New York
|
-$10.2M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$7.98M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.68M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$4.44M |
TARS Hedge Fund Activity: Q4 2023 in Review
116 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q4 2023, worth a combined $652M — up 23% from $529M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new TARS positions and 17 closed out — a net gain of 11 holders — while 48 added to existing stakes and 22 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $31.5M. The largest seller was Deerfield Management, exiting entirely with an estimated $13.4M sold.
- 116 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q4 2023, up from 105 in Q3 2023.
- Funds reported $652M of Tarsus Pharmaceuticals stock for Q4 2023, up 23% quarter-over-quarter.
- 28 funds opened new Tarsus Pharmaceuticals positions in Q4 2023 and 17 closed out, a net change of +11 holders.
- The largest Tarsus Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $31.5M added.
- The largest Tarsus Pharmaceuticals seller in Q4 2023 was Deerfield Management, an estimated $13.4M sold.
Based on aggregated 13F filings for Q4 2023.